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LIVER TRANSPLANTATION IN JEHOVAH’S WITNESSES. O. Detry, A. De Roover, J. Delwaide, P. Damas,
A. Kaba, J. Joris, M. Meurisse, P. Honoré. Dpt of Liver Surgery and Transplantation, CHU Sart Tilman B35, Liège,
Belgium.
Background : For religious reasons, Jehovah’s witnesses (JW) refuse transfusions of any blood product, including
autologous or homologous predonated blood, platelets, fresh frozen plasma, coagulation factor concentrates. However
they may accept solid organ transplantation. In this paper the authors present their experience of liver transplantation
(LT) in JW. Methods : In a 3-year period, 18 JW patients were evaluated for LT. A hematocrit of 40% and a platelet level
of 75.000 /mm3 were considered as the minimal acceptable levels for LT. All patients received perioperative iron 
supplementation and erythropoietin. Two patients had percutaneous spleen embolisation to increase platelet level. High
dose aprotinin was given during LT to limit fibrinolysis and meticulous surgical hemostasis was achieved using 
argon beam coagulation. Continuous circuit cell salvage and reinfusion whereby scavenged blood was maintained in
continuity with the patient’s circulation, was used. Veno-venous bypass was avoided during LT to minimize the 
coagulation disorders. Two patients received recombinant factor VIIa during liver dissection and at reperfusion. 
Results : Five patients were not considered for LT for various reasons. 13 were accepted but 4 died from complications
of liver failure while they were in administrative and medical preparation for LT, before being listed. They had been
looking for a center accepting to transplant them since more than 6 months and were in Child C when seen in our 
center. Two did not get approval from their health care system to get LT in the authors’ center and were not transplanted
in their own country, as they did not find any center agreeing to transplant them. Seven patients were listed for LT and
were successfully transplanted. Four of them were in CHILD C. Five received a cadaveric liver graft and 2 a right lobe
from a live related donor. All adult patients were treated according to the patients’ beliefs. One 6-y-old child received
one unit of blood 15 days after LT, because of symptomatic deep anemia secondary to peritonitis due to perforated 
gastric ulcer. One patient died from aspergillosis and all other patients are alive and well at follow-up. 
Conclusion : LT may be successful in carefully prepared JW patients who should not be a priori excluded from this life
saving procedure. 
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A PROSPECTIVE OPEN, SINGLE ARM, PILOT TRIAL TO ASSESS THE SAFETY AND EFFICACITY OF ORLI-
STAT IN OBESE LIVER TRANSPLANT PATIENTS. F. Nevens (1), G. Vandeplas (1), E. Muls (2), M. Roelands (2),
C. Verslype (1), R. Aerts (3), J. Fevery (1), J. Pirenne (3). (1) Hepatology ; (2) Endocrinology ; (3) Abdominal
Transplantation Surgery, KU Leuven/UZ Gasthuisberg, Leuven.
Background : Obesity an increasingly frequent problem after liver transplantation (LT), decreases patient survival.
Orlistat is an approved treatment for obesity but its safety and efficacity in LT has not been explored. 
Study population : patients transplanted > 1 y with a BMI > 30, despite an hypocaloric regime for > 6 months ; 20 pts
were selected, 19 started. Immunosuppression : tacrolimus or cyclosporine + azathioprine or mycophenolate. Treatment
duration : 6 months 120 mg orlistat tid followed by 120 mg ed during 3 m and further follow up until 12 m. Treatment
was interrupted after 3 m if BMI did not change.
Results : Treatment was well tolerated ; adaptation of tacrolimus was necessary in 6/15 pts (dosis reduction in 5 pts)
and in 2/4 pts under cyclosporine) ; no biochemical toxicity was observed. 3/19 pts were non responders. Evolution of
BMI till end of treatment : 33.8 + 4.3 to 30.7 + 4.1 (p=0.04) ; 3/16 had rapid weight gain after interruption of treatment ;
13/19 pts had a sustained response : evolution of BMI in this group : t0 33.5 + 4.4, t12m 29.8 + 3.8 (p<0.01) and waist 
circumference cm : t0 111.7 + 11.1, t12m 96.3 + 9.5 (p<0.01). 
Conclusion : Orlistat is safe after LT. Minor dosis adjustments of immunosuppression are required. In 68% a sustained
weight loss was observed with a follow-up of 6 months.
